These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7494573)

  • 1. New therapy for ovarian cancer.
    Neijt JP
    N Engl J Med; 1996 Jan; 334(1):50-1. PubMed ID: 7494573
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapy for ovarian cancer.
    Cvitkovic E; Misset JL
    N Engl J Med; 1996 May; 334(19):1269; author reply 1270. PubMed ID: 8606730
    [No Abstract]   [Full Text] [Related]  

  • 3. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for ovarian cancer.
    Parmar MK; Sandercock J
    N Engl J Med; 1996 May; 334(19):1268-9; author reply 1270. PubMed ID: 8606729
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemotherapy for ovarian cancer.
    Lacave AJ; Peláez I; Palacio I
    N Engl J Med; 1996 May; 334(19):1269-70. PubMed ID: 8606731
    [No Abstract]   [Full Text] [Related]  

  • 6. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic factors of ovarian cancer].
    Ochiai K
    Gan To Kagaku Ryoho; 2006 Dec; 33(13):2014-9. PubMed ID: 17197745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study.
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-13-S2-16. PubMed ID: 9045329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recent advances in ovarian cancer chemotherapy from the survival standpoint].
    Hatae M; Onishi Y; Maeda Y; Maeda T; Hirano T; Kamitomo M
    Gan To Kagaku Ryoho; 1995 May; 22(6):718-25. PubMed ID: 7755379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
    Kohn EC; Sarosy GA; Davis P; Christian M; Link CE; Ognibene FP; Sindelar WF; Jacob J; Steinberg SM; Premkumar A; Reed E
    Gynecol Oncol; 1996 Aug; 62(2):181-91. PubMed ID: 8751547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study by the Working Group in Gynecologic Oncology for therapeutic optimization in advanced FIGO IIb-IV ovarian carcinoma: cisplatin-paclitaxel vs. carboplatin-paclitaxel. AGO Protocol Ovar-3].
    Mettler L
    Zentralbl Gynakol; 1996; 118(6):379-4. PubMed ID: 8768017
    [No Abstract]   [Full Text] [Related]  

  • 13. [New world-wide therapy standard determined by German Study Group. Decisive progress in ovarian carcinoma].
    Krankenpfl J; 2003; 41(10-12):238-9. PubMed ID: 14746211
    [No Abstract]   [Full Text] [Related]  

  • 14. Current status of chemotherapy for ovarian cancer.
    Ozols RF
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):61-6. PubMed ID: 7481863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of advanced ovarian clear cell adenocarcinoma responding to cisplatin-cyclophosphamide and paclitaxel-carboplatin].
    Iwasaki K; Komuro Y; Masumoto N; Asaoka K; Ishitani K
    Gan To Kagaku Ryoho; 1999 Sep; 26(10):1483-6. PubMed ID: 10500539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advanced cancer of the ovary. The paclitaxel-cisplatin combination as the first-line standard of treatment].
    Pecorelli S
    Recenti Prog Med; 1999 Jun; 90(6):338-41. PubMed ID: 10399475
    [No Abstract]   [Full Text] [Related]  

  • 18. Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer.
    Markman M
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-24-S11-27. PubMed ID: 9314295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel and cisplatin in ovarian cancer.
    Torri V; Harper PG; Colombo N; Sandercock J; Parmar MK
    J Clin Oncol; 2000 Jun; 18(11):2349-51. PubMed ID: 10829060
    [No Abstract]   [Full Text] [Related]  

  • 20. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
    Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E
    J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.